Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…Abstract Number: 1023 • ACR Convergence 2023
Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes
Background/Purpose: IgG4-related disease (IgG4-RD) is a multi-organ fibroinflammatory disease with an autoimmune basis that can affect essentially any organ. Differences in phenotypic expression between males…Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…Abstract Number: 1542 • ACR Convergence 2023
The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study
Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…Abstract Number: 2377 • ACR Convergence 2023
The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis
Background/Purpose: Older adults with ANCA-associated vasculitis (AAV) have distinct clinical presentations and outcomes when compared to younger adults. Despite a high incidence of AAV in…Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…Abstract Number: 0446 • ACR Convergence 2022
The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with an increased risk of cardiovascular (CV) disease, with MPO- AAV conferring a higher risk of CV events than…Abstract Number: 0700 • ACR Convergence 2022
Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare disease associated with substantial morbidity and mortality.1 To enable outcomes and comparative effectiveness studies using large, phenotypically diverse…Abstract Number: 1087 • ACR Convergence 2022
Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with excess morbidity and mortality. Identifying novel biomarkers may reveal new therapeutic targets and clinically useful biomarkers of disease…Abstract Number: 1091 • ACR Convergence 2022
IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study
Background/Purpose: The Fc portion of IgG tends to be hypogalactosylated among patients with ANCA-associated vasculitis (AAV) compared with healthy controls1,2,3. Glycan modifications may affect antibody…Abstract Number: 1654 • ACR Convergence 2022
Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
Background/Purpose: Hydroxychloroquine (HCQ) is the backbone of SLE therapy, due to its benefits on increasing survival and decreasing lupus flares. In 2011, ophthalmology guidelines recommended…Abstract Number: 0418 • ACR Convergence 2021
Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
Background/Purpose: Renal involvement is common in ANCA-associated vasculitis (AAV). Prior analyses show that end stage renal disease (ESRD) in AAV may be multifactorial. Little is…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »